ANAB - CIK 0001370053
The table below shows ANAPTYSBIO, INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $19.70M | -$135.34M | -$120.80M | -$73.59M | -$45.92M | -$14.16M |
| Capital expenditure | $87.00K | $358.00K | $807.00K | $358.00K | $1.37M | $569.00K |
| Investing cash flow | $228.03M | $95.40M | $144.75M | -$394.85M | $38.84M | $94.47M |
| Dividends paid | - | - | - | - | - |
ANAPTYSBIO, INC reported operating cash flow of $19.70M for fiscal year 2025. That is up 114.6% from -$135.34M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$9.03M (FY 2016) to $19.70M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $68.63M | $456.00K | $50.00M | $0.00 | $0.00 | - |
| Financing cash flow | -$132.61M | $127.05M | -$59.30M | $44.02M | $252.30M | -$879.00K |